Impella 2.5 PMA Gives Abiomed Big Growth Potential For High-Risk PCIs
This article was originally published in The Gray Sheet
Executive Summary
The approval, the first for a percutaneous hemodynamic support device, frees Abiomed's hand to market the miniature blood pump to a relatively broad patient population, analysts note.
You may also be interested in...
FDA Lowers Barrier To Market Penetration For Abiomed's Impella With Expanded Indication
FDA has removed "depressed ejection fraction" from the approved indication for Abiomed's Impella 2.5 and Impella CP based on results from the cVAD registry. The registry data support expanding the FDA-approved indication for the heart pumps during elective and urgent high-risk percutaneous coronary interventions, as well as for patients with cardiomyopathy leading to cardiogenic shock.
No Panel Needed To Expand Impella Into Cardiogenic Shock, Abiomed Says
Abiomed and FDA have agreed to an indication that would allow the firm to market its percutaneous Impella pumps for circulatory support of patients in cardiogenic shock following acute myocardial infarction or cardiac surgery, and no advisory panel will be needed before FDA makes an approval decision, the company says.
Dueling Journal Commentaries Revisit FDA Approval of Abiomed's Impella
The pieces in JAMA Cardiology consider the merits of FDA's "515 Program Initiative" to classify preamendment devices and its application to a minimally invasive ventricular assist device.